Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Innovation And NHS Dodge Axe In U.K. Spending Review, But There Is A Price To Pay

This article was originally published in The Pink Sheet Daily

Executive Summary

Science R&D spending will be maintained at current levels but amount to be allocated for pharmaceuticals unclear.

You may also be interested in...



NICE Likely To Lose Cost-Watchdog Status By 2013

The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.

NICE Likely To Lose Cost-Watchdog Status By 2013

The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.

NICE Likely To Lose Cost-Watchdog Status By 2013

A new value-based pricing system will make NICE's cost-assessment role redundant, say U.K. ministers.

Related Content

Topics

UsernamePublicRestriction

Register

PS071341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel